1. Introduction and Relevance
Infectious diseases and cancer are leading causes of mortality and our ability to combat them is compromised due to the emergence of antibiotic-resistant strains of bacteria and chemotherapy-resistant cancer cells. Combined with the scarcity of new classes of antibiotics due to the abandonment of antibacterial research by pharmaceutical companies (Williams and Bax, 2009) and the lengthy development time lines to market (Projan and Bradford, 2007), there is an urgent need for alternative therapeutics. Cationic antimicrobial peptides (CAPs) have emerged as a promising source of novel therapeutics. Not only do they rapidly kill microbes and cancer cells, they also can modulate host innate immunity to augment clearance of microbes and promote tissue healing resulting from inflammation. Furthermore, they are less prone to resistance than traditional antibiotics (McPhee and Hancock, 2005). Synthetic variants of naturally occurring CAPs, have been designed that exhibit greater selectivity and stability. Here I summarize some of the key features of CAPs, directing the reader to recent pertinent reviews, and focus on characteristics of pleurocidin CAPs that make them attractive for clinical applications.
2. Physical properties of cationic antimicrobial peptides
CAPs are small peptides (10-50 amino acids) with a high content of positively charged (net charge +2 to +9) and hydrophobic (up to 50%) amino acids. Currently over 1800 naturally occurring CAPs from almost all forms of life are annotated in the Antimicrobial Peptide Database (http://aps.unmc.edu/AP/main.php). They can be classified into four structural groups: linear α-helical, β-sheet, loop, and extended structures enriched in certain amino acids such as Arg, Phe, Pro, Gly, Trp and His (Zasloff, 2002). Linear α-helical CAPs such as magainin, LL-37 and pleurocidin are usually unstructured in aqueous solution but adopt an α-helical conformation upon interaction with lipids, thereby acquiring antimicrobial activity. They often contain a hinge in the middle, due to Gly or Pro residues, which enhances the ability of the peptide to enter the cell (Park et al., 2000). CAPs that form stable β-sheet structures contain cysteine residues that are able to form disulphide bonds (usually 1-4 depending on the type of CAP). These include the protegrins, defensins and drosomycins. Looped CAPs, thanatin and brevinin, contain a C-terminal loop carrying a strong positive charge (Fehlbaum et al., 1996). CAPs such as bactenecin, prophenin and indolicidin are enriched in specific amino acids, usually lack cysteines, and form linear or extended coils. CAPs are usually produced as inactive pre-pro-peptides and proteolytically cleaved to release the mature biologically active peptide.
Pleurocidins comprise a family of linear α-helical CAPs consisting of a highly conserved amino-terminal signal sequence and a carboxy-terminal anionic segment flanking the more variable mature peptide of approximately 25 amino acids (Douglas et al., 2001; Patrzykat et al., 2003). This anionic portion may counteract the positively charged mature peptide, thereby keeping it inactive until cleaved. They show some sequence similarity to other fish CAPs, including piscidin, moronecidin and the recently discovered gaduscidin (Browne et al., 2011; Sun et al., 2007). Pleurocidins are encoded as clusters of genes comprised of four exons, and binding sites for transcription factors involved in host defense are located upstream of the promoters (Douglas et al., 2003).
Pleurocidin variant NRC-04 is the best-studied of this family of peptides. Early studies showed that in 25% dodecylphosphatidylcholine (DOPC)/ dodecylphosphatidyl-ethanolamine (DOPE) vesicles, it forms a structure containing between 12% and 24% α-helical content (Yoshida et al., 2001). Supporting this, it was only weakly incorporated into neutral bilayers composed of a 7:3 mixture of DOPC and DOPE; however, it strongly associated with a slightly anionic bilayer of 7:3:1 DOPC, DOPE, and dodecylphosphatidylserine (DOPS), forming well-defined single ion channels (Saint et al., 2002). NMR studies have shown that in 0% DPC, pleurocidin has no identifiable well-defined secondary structure but in 30% TFE and in 10 mM DOPC micelles, it was 25% α-helical and this increased to 95% in 140 mM DOPC (Syvitski et al., 2005). The hydrophobic amino acids residues clustered on approximately 2/3 of the helix and hydrophilic residues on the remaining 1/3 of the helix.
3. Distribution and expression of cationic antimicrobial peptides
3.1. Organismal distribution
CAPs are ubiquitous in nature and play a crucial role in first-line host defense against pathogens. Fish and marine invertebrates, because of their diversity and reliance on non-specific innate immune defenses, have proved to be a particularly good source of novel CAPs with therapeutic potential (Otero-González, 2010; Smith and Fernandes, 2009).
3.2.1. Tissue specificity
In mammals, CAPs are expressed in cells of the skin and mucosal surfaces, as well as blood cells such as platelets, monocytes/macropages, neutrophils, and mast cells (Guaní-Guerra et al., 2010). Tissues often express a cocktail of different CAPs with varying activities and the expression of a given CAP variant may be restricted to a specific cell type (see Wiesner and Vilcinskas, 2010). For example, of the six different α-defensins, four are produced predominantly in neutrophils whereas two are secreted from Paneth cells of the small intestine.
Fish CAPs such as pleurocidin are expressed in a broad range of tissues and cell types including epithelial, immune and blood cells (Browne et al., 2011). Pleurocidin is produced by epithelial cells of the skin and gut (Cole et al., 1997; Douglas et al., 2001) as well as circulating immune cells (Murray et al., 2007). Interestingly, different pleurocidin variants are produced by different cell types (Douglas et al., 2003), underscoring the importance of screening multiple tissues to uncover the true diversity of CAPs.
3.2.2. Developmental stage
The presence of CAPs in neonates, who have yet to develop adaptive immunity, provides enteric protection and impacts the composition of the commensal microflora. Milk lactoferrin, from which the CAP lactoferricin is produced by pepsin cleavage in the stomach, plays a major role in maternal and innate immunity (Jenssen and Hancock, 2009). Dermicidin YP-30 is important for maternal and early post-natal protection (Wiesner and Vilcinskas, 2010). Mouse cathelin-related antimicrobial peptide undergoes a developmental switch from constitutive intestinal epithelial expression in neonates to Paneth cell expression in adult intestinal crypts (Menard et al., 2008).
Pleurocidin transcripts were detected early in development of winter flounder, when larvae are most susceptible to pathogen-induced mortality, and showed a progressive increase as development proceeded to adulthood (Douglas et al., 2001). Furthermore, different pleurocidin variants were present at different stages of development, indicating that screening of CAP production from various developmental stages of an organism is an excellent means of discovering novel peptide variants.
3.2.3. Constitutive or inducible
CAPs may be expressed constitutively or inducibly in response to stress, poor nutrition, inflammation (Wehkamp et al., 2003), injury or microbial infection (Redfern et al., 2011; Zasloff, 2006), and exposure to environmental factors such as zinc (Talukder et al., 2011) or vitamin D (White, 2010). For example, hCAP-18/LL-37 protein and mRNA expression was up-regulated in neutrophils that had migrated to the inflamed gingival tissues of patients with chronic periodontitis (Turkoglu et al., 2011) and mycoplasma infection induces cathelicidin expression in neutrophils of infected mice (Tani et al., 2011). Interestingly, increased endogenous glucocorticoid levels induced by psychological stress reduce CAP expression in mice, leading to increased susceptibility to infection (Aberg et al., 2007).
Expression of fish CAPs is also regulated in response to stress and disease (Douglas et al., 2003a; Sun et al., 2007), and novel variants are often induced by such stressors. Monitoring levels of CAPs in aquaculture settings provides early warning of immunosuppression due to chronic stress, and conversely induction of CAPs provides protection against anticipated stressful situations such as handling (Noga et al., 2011).
4. Mode of action of cationic antimicrobial peptides
4.1. Membrane effects
CAPs can cause lysis of biological membranes or cross membranes by spontaneous lipid-assisted translocation. The initial interaction is electrostatic between the cationic residues of the peptide and the negatively charged constituents of the target cell, whether they are in an outer bacterial envelope, a viral envelope or a eukaryotic cell membrane. Because of the high proportion of uncharged zwitterionic lipids and sterols in normal eukaryotic membranes, however, these membranes are not as susceptible as negatively charged bacterial membranes or cancer cell membranes, which contain elevated levels of negatively charged sialylated glycoproteins (van Beek et al., 1973),
Upon binding, the peptide assumes an amphipathic secondary structure that facilitates membrane disruption. A number of mechanisms have been proposed including micelle formation by the carpet model (Shai, 2002) and pore formation by the barrel-stave and toroidal pore models (Brogden, 2005; Hadley and Hancock, 2010). Additional variations on these initial models for bacterial membrane interactions have been proposed including localized membrane disorganization by the aggregate model (Hancock and Rozek, 2002), the formation of disordered toroidal pores, charged lipid clustering, membrane thinning, electroporation, non-lytic membrane depolarization, anion carriers and oxidized lipid targeting (Nguyen et al., 2011).
Pleurocidin has been proposed to act via the toroidal pore model, based on its interactions with model membranes (Saint et al., 2002). This finding is supported by NMR studies that show that in DOPC pleurocidin exists as a very large species, probably composed of 20-25 aggregating molecules (Syvitski et al., 2005), indicating that at high concentrations pleurocidin forms pores within the membrane environment or disrupts the membrane by aggregation. A more recent study proposed that CAPS similar to pleurocidin such as magainin 2 adopt a surface alignment in mixed zwitterionic/anionic membranes and forms disordered toroidal pores (Leontiadou et al., 2006). The interaction of pleurocidin with the anionic lipid phosphatidylglycerol (PG) rather than the zwitterionic lipid phosphatidylethanolamine (PE) in mixed membranes, resulting in disruption of membrane integrity, was confirmed using NMR (Mason et al., 2006). Interestingly, the three His residues, which become protonated at acidic pH, play no role in membrane disruption, most likely due to their position along the spine of the helix where they would be unlikely to interact with lipid head groups.
The Gly13 residue in the middle of pleurocidin confers flexibility between a longer α-helix at the amino terminus and a shorter α-helix at the carboxy terminus allowing it to interact with the negatively charged phospholipid membranes (Yang et al., 2006). Replacing Gly13 with Ala removes this hinge region, resulting in a much higher α-helical content and loss of cell selectivity. This analog is hemolytic and interacts with both negatively charged (mimicking bacterial and cancer cell membranes) and zwitterionic (mimicking erythrocyte and normal mammalian cell membranes) phospholipids. Similarly, substitution of both Gly13 and Gly17 by Ala results in a large increase in α-helicity and a correspondingly dramatic increase in hemolytic activity, indicating that the hinge region facilitates flexibility and confers bacterial cell selectivity (Lim et al., 2004a). It is interesting that Gly13 is conserved in 15 of the 26 identified pleurocidin variants whereas Gly17 is conserved in only 6, indicating that Gly13 plays the more important role in peptide function.
Sterols are commonly found in eukaryotic but not bacterial cell membranes, and their presence in anionic mixed membranes reduces the ability of pleurocidin to insert even though the peptide maintains its α-helical configuration (Mason et al., 2007). Cholesterol, found in membranes of higher eukaryotes, was shown to be more effective than ergosterol, commonly found in those of fungi and certain protozoa, in reducing insertion of CAPs. These differences in membrane sterol content explain the differential sensitivity of bacteria, lower eukaryotes and higher eukaryotes to CAPs such as pleurocidin. Using a fluorescent membrane probe, pleurocidin has been shown to structurally perturb the plasma membrane of the fungal pathogen
Structural modelling predicted that only 12 of the 26 described pleurocidin variants formed amphipathic α-helices and killing assays showed that these were cytotoxic to HL-60 human leukemia cells, resulting in rapid and complete killing (Morash et al., 2011). Cell death was non-apoptotic and probably occurred by the formation of ion channels that dissipated the membrane potential and led to cell lysis. The active pleurocidin variants were the more highly charged (>+6.5) members of the family; interestingly only one of them was also hemolytic. The anti-cancer activities of two pleurocidin variants (NRC-03 and NRC-07) against breast cancer cells involve binding to negatively charged cell-surface molecules (Hilchie et al., 2011).
4.2. Intracellular effects
A number of CAPs, when administered at low doses, are able to penetrate the bacterial membrane and disrupt metabolic processes (see Marcos and Gandia, 2009; Nicolas, 2009). CAPs can assume different structures whilst exerting their inhibitory effects. For example, when bound to DNA, buforin II assumes an extended form whereas magainin and pleurocidin assume an α-helical form and bind DNA less effectively (Lan et al., 2010). Combinations of CAPs that exert their effects on different targets may exhibit synergy, and provide more potent killing activity.
Pleurocidin usually causes membrane disruption at high concentrations whereas at low concentrations, it can translocate into the cytoplasm without causing cell lysis and exert its effects intracellularly, inhibiting DNA, RNA and protein synthesis (Patrzykat et al., 2002). The intracellular effect of pleurocidin NRC-03 has since been probed using zebrafish embryos, and shown to target the mitochondria and generate superoxide (Morash et al., 2011). TUNEL staining indicates that the DNA of some cells becomes degraded, whereas other cells undergo rapid lysis and cell death without DNA fragmentation. Pleurocidin variants NRC-03 and NRC-07 cause mitochondrial membrane damage and production of reactive oxygen species (ROS) in MDA-MB-231 breast cancer cells (Hilchie et al., 2011).
4.3. Receptors and binding proteins
In most cases, killing is by nonreceptor-mediated mechanisms since all D-amino acid enantiomers are generally as active as the natural L-amino acid peptides. However, stereospecific receptor-mediated translocation has been described (Nicolas, 2009) and some CAPs transduce their effects via signaling networks upon interaction with receptors. Quite a diversity of receptors have been described, possibly reflecting the diversity in peptide structures. Uptake of apidaecin into Gram negative bacteria is proposed to by an energy-dependent mechanism involving a permease or transporter (Castle et al., 1999). The detection of peptide:receptor complexes is technically very difficult but some receptors have been identified. For example, the outer membrane protein OprI from
Activation of mast cells by pleurocidin is G protein-dependent and proposed to involve FPRL1 and G protein coupled receptor signaling pathway (Kulka, unpub). The observation that pleurocidin can bind and activate FPRL1 has some important implications for human disease. The FPRL1 receptor subtype is also a receptor for the bacterially-derived peptide fMLP (N-formyl-L-methionyl-L-leucyl-L-phenylalanine) making it an important innate immune receptor (Selvatici et al., 2006). FPRL1 activates key components of the innate immune system and is responsible for chemotactic responses, superoxide anion production and degranulation by neutrophils, macrophages and mast cells. FPRL function has been shown to be important in chronic obstructive pulmonary disease (COPD) due to cigarette smoking (Cardini et al., 2012). FPRL1 can also transactivate epidermal growth factor receptors (EGFR) making them a potentially important target in lung cancer (Cattaneo et al., 2011).
5. Biological activities and therapeutic applications of cationic antimicrobial peptides
Because of their rapid, broad spectrum bactericidal action, potency, and low host cytotoxicity, CAPs have elicited much excitement as alternatives to current antibiotics, particularly in the fight against antibiotic-resistant pathogens (Nijnik and Hancock, 2009). CAPs can cause bacterial cell death by disrupting the bacterial membrane, by entering the cell and inhibiting intracellular targets, or by stimulating the immune system to eliminate an infection. They can be used alone or together with other antibacterial agents, with which they frequently synergize.
Pleurocidins show broad-spectrum antimicrobial activity at micromolar concentrations and also show synergistic activity with several antibiotics (Cole et al., 2000; Douglas et al., 2003; Patrzykat et al., 2003). In contrast to many CAPs, pleurocidin is insensitive to NaCl concentrations up to 150 mM, and may therefore have application in relatively high-salt bodily fluids and in treatment of lung infections in patients with cystic fibrosis, who have even higher NaCl content (Goldman et al., 1997).
Recent studies have shown that pleurocidin possesses considerable activity against oral microorganisms growing both planktonically and as a biofilm, even in the presence of saliva (Tao et al., 2011). Incorporation of a targeting moiety to pleurocidin NRC-04 has significantly increased its specificity towards
Foodborne infections, especially those of seafood are a major health problem, yet only one CAP, nisin, has been approved by the FDA for use as a food preservative and it has only limited activity against Gram-negative bacteria or fungi (Burrowes et al., 2004).
Pleurocidin was tested against Gram-positive and Gram-negative bacteria of interest in food safety and shown to be highly effective against 17 of 18 strains, particularly the fish spoilage bacterium
The antifungal properties of CAPs have been recognized for some time (De Lucca and Walsh, 1999); however, it is only recently that the mechanism of action has been elucidated. While some CAPs such as LL-37 kill fungal cells by lysing the cell membrane, others such as histatin and defensins 2 and 3 kill in an energy-dependent and salt-sensitive fashion without cell lysis (den Hertog et al., 2005; Vylkova et al., 2007). Magainin 2 and dermaseptin S3(1-16) also cross the cell membrane and interfere with DNA integrity (Morton et al., 2007a; Morton et al., 2007b). Histatin 5, lactoferrin, arenicin-1 and several other CAPs inhibit mitochondrial respiration and induce the formation of ROS and subsequent apoptosis in
Attempts to improve antifungal activity of CAPs have resulted in structural analogs with increased selectivity towards fungi and less host cytotoxicity. Hydrophobicity was shown to be a crucial factor in the antifungal activity of a series of CAP analogs against zygomycetes vs ascomycetes (Jiang et al., 2008). Synthetic, non-peptidic analogs of naturally-occurring CAPs have shown potent activity as anti-
Pleurocidin also possesses activity against
Enveloped viruses are often susceptible to attack by CAPs. Four different linear CAPs were shown to inactivate vaccinia virus by removal of the outer membrane, thereby rendering the inner membrane susceptible to neutralizing antibody against the exposed antigens (Dean et al., 2010). Novel HIV-1-inhibitory peptides have recently been identified by screening the APD Antimicrobial Peptide Database for CAPs with promising antiviral properties. This uncovered 30 candidate CAPs which, when synthesized and tested, resulted in 11 peptides with EC50<10 μM against HIV-1 (Wang et al., 2010). Some CAPs are able to exert antiviral effects by blocking cell surface receptors used for viral entry. For example, the polyphemusin analog T22 binds CXCR4 on T cells and prevents T cell line-tropic HIV-1 entry (Murakami et al., 1997).
The antiviral activity of pleurocidin variants has been tested against vaccinia virus grown in HeLa cells and four lead candidates were identified based on viral inhibition without HeLa cytotoxicity at both high and low multiplicity of infection (MOI) (Johnston, pers. comm.). At the more biologically relevant low MOI, two peptides were inhibitory with an IC50< 1 μg/ml. Further studies are required to determine the mechanism by which pleurocidin exerts its antiviral effect.
The anti-parasitic properties of magainins and cecropins have been known for over twenty years and have subsequently been reported for many other CAPs (Harrington, 2011; Mor, 2009). CAPs are able to traverse the membranes of parasite-infected erythrocytes and are proposed to change the properties of the parasite cell membrane, cause membrane lysis, or become internalized and interfere with biological processes. BMAP-28, BMAP-27 and the less cytotoxic truncated derivative BMAP-18 have recently been shown to possess excellent
Pleurocidin inhibited the bloodstream form of
In contrast to conventional chemotherapy drugs that target all actively proliferating cells, CAPs can show selective cytotoxicity towards cancer cells including dormant, slow-growing, and multidrug resistant cells (see Hoskin and Ramamoorthy, 2008)). Both apoptotic (Jin et al., 2010) and non-apoptotic (Ceron et al., 2010; Hilchie et al., 2011; Morash et al., 2011) mechanisms have been proposed. The α-helical CAP, temporin-1CEa, exhibits cytotoxicity towards all of 12 tested human carcinoma cell lines in a concentration-dependent manner, yet no significant cytotoxicity to normal human umbilical vein smooth muscle cells at concentrations that showed potent antitumor activity (Wang et al., 2011). The basis for selectivity is thought to be the presence of phosphatidylserine, which is exposed on non-apoptotic tumor cells including malignant metastatic cells and primary cell cultures. Susceptibility of metastatic cells suggests that CAPs may be useful in treating metastatic as well as primary cancers (Riedl et al., 2011).
In addition to direct killing of cancer cells, CAPs can affect T-cell dependent tumor regulation. Recently, intratumoral administration of a lactoferricin derivative into lymphomas established in mice resulted in tumor necrosis, infiltration of inflammatory cells, and regression of tumors. Transfer of spleen cells from treated mice provided long-term, specific T cell-dependent immunity against the lymphoma, suggesting therapeutic vaccination against cancer using CAPs may be possible (Berge et al., 2010). In contrast, LL-37 was able to induce apoptosis of T regulatory cells, thus inhibiting their immune suppressor activity and thereby enhancing the anti-tumor response (Mader et al., 2011).
Pleurocidins selectively killed human leukemia cells at low concentrations (<32 μg/mL) (Morash et al., 2011) as well as multiple breast cancer cell lines (Hilchie et al., 2011) by a predominantly membranolytic mechanism. Disruption of the cell membrane also augmented the activity of the chemotherapeutic cisplatin, presumably by enhancing access to the nucleus. Furthermore, when administered intratumorally into breast cancer xenografts in mice, pleurocidin inhibited tumor growth and induced tumor necrosis, while not causing observable adverse effects on the mice (Hilchie et al., 2011). These advantageous properties indicate that pleurocidins should be pursued as novel anticancer agents.
CAPs show multiple activities associated with modulation of the immune system (Jenssen and Hancock, 2010; Yeung et al., 2011) and have been postulated to represent an evolutionary link bridging innate and adaptive immune responses (Selsted and Ouellette, 2005). CAPs are directly chemotactic for immune cells and also stimulate chemokine and cytokine secretion (Lai and Gallo, 2009). Some CAPs are able to boost protein antigens and vaccines that have low immunogenicity by inducing proinflammatory cytokines such as TNF, IFN and IL-1β (Kindrachuk et al., 2009; Mutwiri et al., 2007; Tavano et al., 2011), suggesting that they would be good adjuvants (Huang et al., 2011; Li et al., 2008). CAPs play a critical role in wound healing (Steinstraesser et al., 2008), promoting keratinocyte migration (Aung et al., 2011a), re-epithelialization (Hirsch et al., 2009), deposition of extracellular matrix (Oono et al., 2002), and angiogenesis (Koczulla et al., 2003). Human β-defensins and LL-37 are able to stimulate mast cells, and recently the neuroendocrine CAP catestatin has been reported to induce migration and degranulation of mast cells, release of lipid mediators and production of cytokines and chemokines (Aung et al., 2011b). CAPs also show promise in counteracting sepsis, a major cause of morbidity and mortality in hospitalized patients. For example, intraperitoneal injection of LPS-sensitized mice with S-thanatin reduced serum endotoxin and TNF-α levels, resulting in 100% survival (Wu et al., 2011).
Pleurocidin has a proinflammatory effect in fish cells
Pleurocidins activate human mast cells to release granule contents such as histamine and proteases (Kulka, per. comm.) both of which are important in allergic inflammation and tissue hometostasis. Mast cells are critical regulators of the tissue microenvironment capable of responding to many different stimuli including allergens and releasing a huge variety of pro-inflammatory and immunomodulatory mediators. Interestingly, pleurocidin activation of mast cells is unique from that of allergens. Allergens bind to and crosslink surface high affinity immunoglobulin E receptors (FcεRI), which activates increases in intracellular calcium and initiates several signaling pathways. Whereas FcεRI activation results in degranulation, arachidonic acid metabolite release and pro-inflammatory mediator production, pleurocidin activation of FPRL1 initiates degranulation and production of relatively small amounts of chemokines. Furthermore, whereas FcεRI engagement does not activate mast cell chemotaxis, pleurocidins modify adhesion via the fibronectin receptor (CD29) and promote mast cell migration. This suggests that pleurocidins activate selective signaling pathways in mast cells and may be useful tools in targeted mast cell-dependent therapy.
5.7.1. Hemolysis and host cell lysis
Although most CAPs are not hemolytic or cytolytic at the concentrations used for killing microbes or cancer cells, some do exhibit that characteristic, melittin being the most notorious (Tosteson et al., 1985). Magainin also forms pores in human cell membranes and enters the cell within minutes, accumulating in the nucleus and mitochondrion (Imura et al., 2008). Bovine myeloid antimicrobial peptides BMAP-27 and BMAP-28 at 10 times minimal inhibitory concentration (MIC) are toxic towards human erythrocytes and polymorphonuclear cells and induce apoptosis in transformed cell lines and
Hemolysis assays of 26 variants of pleurocidin showed that only one, a histidine-rich variant NRC-19, showed any ability to lyse red blood cells up to a concentration of 128 μg/mL, well above the concentrations required to kill bacterial and cancer cells (Morash et al., 2011). The selectivity of these peptides indicates that they would be excellent candidates as antibacterial and anti-cancer agents.
While many CAPs can reduce sepsis, some actually exacerbate the problem. This is because they are so effective at killing bacterial cells that they cause the release of endotoxin from lysed cells, eliciting an excessive inflammatory response (Risso et al., 1998; Steinstraesser et al., 2003).
Preliminary studies using a mouse cytokine array showed that pleurocidin variants NRC-03 and NRC-08 are able to repress LPS-induced TNF-α and IL-10 secretion from mouse RAW264.7 macrophages, indicating that they may be considered for the control of sepsis (Carroll, Patrzykat & Douglas, pers. comm.).
6. Isolation and discovery of cationic antimicrobial peptides
6.1. Traditional biochemical purification
Standard biochemical techniques for isolation of small peptides have been used to isolate CAPs from tissues, skin secretions and other biological fluids. Briefly, tissue lysates or fluids are diluted in 0.1% trifluoroacetic acid (TFA) and extracted under ice-cold acid conditions. After centrifugation, the acidic supernatant is loaded on a C18 column and the peptide eluted with increasing acetonitrile (5-80%) in 0.05% TFA. Those fractions with antimicrobial activity are pooled and further purified by reverse-phase HPLC with increasing acetonitrile (5-55%) in 0.05% TFA. The material in absorbance peaks is then pooled, dried under vacuum and reconstituted in MilliQ water for mass and sequence analysis using mass spectrometry and automated Edman degradation.
Pleurocidin was originally isolated from homogenates of the skin and mucus secretions of winter flounder using C18 chromatography followed by size fractionation on Sephadex G-50 (Cole et al., 1997). Biologically active fractions were pooled and subjected to strong cation exchange HPLC and then reversed phase HPLC.
6.2.Genomics approaches to antimicrobial peptide discovery
Once even a partial amino acid sequence of a CAP is known, genomic strategies can be employed to identify and isolate DNA sequences encoding CAPs. This can involve screening of cDNA and genomic libraries using oligonucleotide probes or amplification of CAP-encoding sequences from genomic or cDNA by PCR (Iwamuro and Kobayashi, 2010). CAP-encoding sequences can also be identified in genomic and EST sequencing databases by similarity searching using bioinformatics search engines such as BLAST (Browne et al., 2011; Fernandes et al., 2010). Full-length cDNA sequences can then be obtained by 5’- and 3’-RACE. The identification of 28 new human and 43 new mouse β-defensin genes was achieved using a computational search tool to find conserved motifs in draft genome sequences (Schutte et al., 2002).
Pleurocidin was originally cloned from cDNA and genomic libraries using degenerate oligonucleotide probes (Cole et al., 2000; Douglas et al., 2001) or PCR amplicons encoding individual pleurocidin variants (Douglas et al., 2003). Additional pleurocidin variants were amplified by PCR from cDNA of different flatfish species using primers corresponding to the conserved amino-terminal signal peptide and carboxy-terminal anionic propiece (Patrzykat et al., 2003). At least 30 variants have now been cloned (Figure 3).
In silico discovery and rational peptide design
7. Production of cationic antimicrobial peptides
7.1. Peptide synthesis
Isolation of CAPs from the native producer is not feasible on the scale necessary for investigating therapeutic value and pharmaceutical potential. Therefore, CAPs are usually synthesized by standard solid-phase methods using 9-fluorenyl-methoxycarbonyl (F-moc) protecting groups, cleaved from the resin with 95% trifluoroacetic acid, purified by reverse-phase high performance liquid chromatography using an acetonitrile gradient, and the mass is verified by mass spectrometry. Although synthesis of linear α-helical peptides is fairly routine, good yields of CAPs that require cysteine oxidation to form the correct disulphide bonding pattern are rarely obtained (Tay et al., 2011). Modifications such as carboxy-terminal amidation, biotinylation, fluorescent labeling, incorporation of D-amino acids, acylation, etc. are available for synthetic peptides.
Production of CAPs in bacteria using recombinant technology, by definition, is a challenge as they inhibit or kill the host bacteria and bacterial proteases can degrade them. Recombinant technology, particularly of tagged fusion peptides, has been used successfully to produce high yields of pure CAP at relatively low cost (Ingham and Moore, 2007). Factors to be considered include optimization of promoter sequence and codon usage from the source organism to bacterial host, signal peptide, tag, fusion partner, ease and cost of cleavage, and cost of subsequent purification steps. A recent approach involving secretion of the tagged SUMO-CAP hybrid into the medium followed by removal of the mature CAP by sumoase protease has been particularly successful in large-scale production of several CAPs (Bommarius et al., 2010; Li et al., 2009). In general, production of α-helical CAPs without disulfide bonds and easily cleavable from their fusion partner has proved to be the most straightforward and cost-effective. A recent report of expression of human β-defensin 28 in
Pleurocidin has been successfully expressed as a PurF fusion peptide in inclusion bodies, generating milligram quantities of pure peptide (Bryksa et al., 2006). By incorporating (15NH4)2-SO4 as the sole nitrogen source in the growth medium, structural elucidation of the uniformly 15N-labelled peptide by NMR was greatly facilitated (Syvitski et al., 2005).
Fungi such as
Production of pleurocidin was attempted using this system; however, no recombinant peptide was recovered, despite correct integration of the pleurocidin sequence into the yeast genome and normal transcription (Burrowes et al., 2005).
7.2.3. Animal cells
Production of CAPs in animal cells has the advantage of accurate processing of the recombinant peptide and addition of post-translational modifications. However, there are few reports of CAP production using this approach. The insect cell/baculovirus system has been used to produce recombinant human β-defensins (Feng et al., 2005) and biologically active hepcidin was successfully expressed, processed and secreted in human embryonic kidney cells (Wallace et al., 2006). The complete pleurocidin pre-pro-peptide gene was cloned into a carp cell line under the control of the carp β-actin promoter. The precursor peptide was expressed continuously for over two years and the mature peptide was secreted into the medium (Brocal et al., 2006).
7.3. Transgenic organisms
Early attempts were made to express CAPs in the milk of transgenic mice (Yarus et al., 1996), tissues of catfish (Dunham et al., 2002), and leaves of tobacco (Yevtushenko et al., 2005) and rice (Imamura et al., 2010); however, while the recombinant CAPs were able to confer pathogen resistance to the host organism, these systems are not designed for large-scale production of CAPs for human applications.
8. Modifications to enhance biological activity and stability
8.1. Amino acid substitutions, additions and deletions
Modification of the amino acid sequence of CAPs to change the charge, hydrophobicity and bulkiness can have dramatic effects on their ability to interact with membranes and exert their biological activity. Amidation of the carboxy terminus usually results in enhanced activity by increasing the net positive charge but has a negligible effect on protease susceptibility. On the other hand, N-terminal acetylation significantly increases resistance to aminopeptidases but decreases antimicrobial activity (Nguyen et al., 2010). In general, high hydrophobicity confers hemolytic and cytotoxic properties on CAPs (McPhee and Hancock, 2005). The effect of amino acid substitutions on antimicrobial vs hemolytic activity has been comprehensively evaluated using a series of rationally designed CAPs of 20 amino acids that differ in charge, polar angle, hydrophobicity and hydrophobic moment (Chou et al., 2008). Increasing the His content of clavanin resulted in an acid-activated CAP that showed enhanced activity against the caries-producing pathogen,
Naturally occurring pleurocidins have variable amino acid sequences that confer different activities against microbes and cancer cells (Morash et al., 2011; Patrzykat et al., 2003). Alignment of the amino acid sequences of the mature peptides revealed conserved positions that could be of importance in bioactivity. For example, the highly conserved Gly13 residue in the middle hinge region is important for α-helicity (Lim et al., 2004b) and the hydrophobic amino acids in the N-terminal region are more crucial for antifungal activity than those in the C-terminal region (Lee and Lee, 2010). Replacement of Ser14 by His improved the activity of a targeted pleurocidin towards
8.2. Non-natural amino acids and enantiomers
Replacement of L-amino acids by their D counterparts generally does not diminish biological activity but does confer protease resistance on the peptide (Lee and Lee, 2008; Park et al., 2010). Retro-inversion, in which amino acid stereochemistry is changed as well as peptide bond direction yielding isomers with similar side chain topology to the native peptide, has generally met with limited success although partially modified retro-inverso peptides show more promise (Fischer, 2003). Incorporation of non-natural amino acid analogs (Knappe et al., 2010; Marsh et al., 2009) is also effective. Recently, a series of CAPs containing Tic-Oic dipeptide analogues was developed to combat 11 potential bio-terrorism and drug-resistant strains of bacteria (Venugopal, 2010). These CAPs were metabolically stable, potent, and showed selectivity for bacterial relative to host cell membranes.
Replacement of L-Lys and L-Arg residues with D-Lys and D-Arg in pleurocidin conferred resistance to digestion by trypsin but also abolished activity, presumably because the α-helical structure was disrupted by the inclusion of just a subset of amino acids (Douglas, unpub.). In support of this, an all D-amino acid analog of pleurocidin showed proteolytic resistance and double the antifungal (Jung et al., 2007) and antibacterial (Lee and Lee, 2008) potency. Similarly, an all D-amino acid analog of pleurocidin NRC-03, showed improved activity against breast cancer cells compared to the natural L-form peptide (Hilchie, Hoskin, unpub).
Peptidomimetics such as β-peptides and peptoids have been designed that maintain the amphiphilic structure and antimicrobial activity and are resistant to protease degradation; these abiotic structures exhibit
Addition of fatty acid chains to the termini of CAPs can increase their antibacterial activity or endow them with antifungal activity. Linear oligomers consisting of alternating uncharged and cationic Lys residues displayed varying degrees of antibacterial, antifungal and hemolytic activity when they were N-acylated, depending on the length of the acyl group and the different degrees of oligomerization that were induced (Shai et al., 2006). Addition of fatty acids of increasing lengths to magainin increased the extent of oligomerization of the resulting lipopeptide, and concurrently the antifungal activity.
Cyclisation by, for example, disulfide bridge formation or head-to-tail backbone cyclization, results in a more constrained peptide structure that is less susceptible to protease degradation (Nguyen et al., 2010). Cyclisation of two cationic hexapeptides, including the active portion of lactoferricin, was found to be highly effective for both serum stability and antimicrobial activity. Interestingly, disulfide cyclization resulted in more active peptides while backbone cyclization resulted in more proteolytically stable peptides. The modifications did not result in hemolytic activity, thereby making them attractive therapeutic candidates. Dendrimers of CAPs have enhanced ability to permeabilize membranes and are stabler than monomeric forms (Pieters et al., 2009).
8.6. Targeted and hybrid peptides
One of the drawbacks of antibiotic use is the deleterious effect broad spectrum antibiotics have on the normal microflora, which often allows opportunistic pathogens such as
We have used this approach to combine the minimal targeting portion of CSP with the killing domain of pleurocidin variant NRC-04 to treat
9. Advantages and limitations of cationic antimicrobial peptides
CAPs exert rapid, broad spectrum, bactericidal activity at micromolar concentrations and are valuable weapons in the fight against antibiotic-resistant microbes e.g. MRSA. In addition, targeted CAPs may be used as probiotics to eradicate pathogenic bacteria while leaving normal flora unaffected. Their ability to kill fungi, viruses and parasites is also beneficial clinically. Many CAPs neutralize endotoxin and can be used to counteract sepsis or to enhance host defenses through immunomodulatory effects. Increased innate clearance of microbes results in less bacterial debris (van der Does et al., 2010) and ensuing inflammation (Andra et al., 2006). Their application both in killing tumor cells and in enhancing host anti-tumor responses is gaining momentum (Yeung et al., 2011).
CAPs have a low propensity to induce microbial resistance, mainly due to their multiple targets and mechanisms of action. CAPs are usually expressed in high concentrations only at sites of infection; continuous exposure of microbes, which often leads to resistance, is therefore minimized. In addition, cocktails of several different CAPs are often produced simultaneously, leading to increased microbial killing.
Despite this, some reports on the emergence of resistance have appeared. These include reduction in bacterial cell surface negative charge, secretion of exoproteases and induction of transporters (see Nizet, 2006; Peschel and Sahl, 2006), all of which require significant expenditure of metabolic energy by the microbe. In most cases, the resistance that arises is very low compared to conventional antibiotics.
In Gram negative organisms such as
Solid phase peptide synthesis is expensive and companies seeking regulatory approval for peptides in their pipelines require suppliers that adhere to good manufacturing practice (GMP) regulations, which also adds to the cost. However, there have been many advances in synthetic chemistry that have significantly reduced the cost of not only peptides but also non-peptide mimics and peptoids, and the lower operating costs of suppliers in Asia has resulted in more affordable peptides (Eckert, 2011).
Although CAPs represent a promising class of therapeutics, they have several
9.5. Side effects
Some CAPs exhibit
10.Clinical use and commercialization
A number of CAPs and synthetic CAP analogs such as pexiganan™ (magainin derivative), omiganan™ (indolicidin derivative), novispirin™ (cathelicidin derivative) and iseganan™ (protegrin-1 derivative) are now in commercial development. Several recent reviews describe the companies, their products and their progression through clinical trials (Eckert, 2011; Kindrachuk and Napper, 2010; Yeung et al., 2011; Zhang and Falla, 2010). Some candidates show great promise in the treatment of such disorders as HIV-associated oral candidiasis, acne, wound infections, diabetic foot ulcers, and oral biofilms. However, the inability to demonstrate advantage over existing therapeutics has resulted in failure of a number of CAPs at Phase III clinical trials. As appropriate formulations, bioassays and endpoints are established, the probability that these promising products will receive regulatory approval will improve.
Because of systemic toxicity and bioavailability issues as well as the diverse and complex mechanisms of action, the majority of CAPs have been developed as topical formulations e.g. for diabetic foot ulcers (Lipsky et al., 2008) and skin infections (Falla and Zhang, 2010
). Depending on the application, a number of different ways of formulating CAPs can be envisioned (Eckert, 2011). CAPs have been incorporated into lens preservation and artificial tear solutions (Huang et al., 2005) and aerosols (Lange et al., 2001). Inclusion of CAPs in coatings (Kazemzadeh-Narbat et al., 2010), polymers (Gao et al., 2011), hydrogels (Roy and Das, 2008), liposomes (Lange et al., 2001), micro- and nanoparticles (Bi et al., 2011; Garlapati et al., 2011) and even chewing gum (Faraj et al., 2007) also represent promising formulations. Long-term activity has been achieved by covalent immobilization of gramicidin A on functionalized gold surfaces and resulted in inhibition of Gram-positive and Gram-negative bacteria and the yeast
CAPs can also be used in combination therapies with each other or with approved antibiotics. For example, cecropin B enhanced the activities of beta lactams in rat septic shock models (Ghiselli et al., 2004). Cecropin A and magainin 2 administered together showed
Pleurocidin showed synergistic activity with inducible histone peptides and lysozyme in a salmonid
10.3. Targeted delivery
CAPs with cell-penetrating properties are under development as vectors for translocation of bioactive cargos with inherently poor membrane-crossing abilities into eukaryotic cells (Splith and Neundorf, 2011). Delivery of CAP-modified liposomes containing therapeutics to bacteria has also been reported, e. g. bacteria-targeted delivery of photodynamic antimicrobial chemotherapy to improve efficiency against MRSA and
CAPs show exciting promise as novel therapeutic agents, particularly in the fight against antibiotic-resistant bacteria and cancer and as immunostimulants. However, translation to clinical use has been hampered by concerns over stability, cost, systemic administration, known toxicity, and unknown long-term toxicity. The applications that show the most promise are those involving topical applications, particularly in combination with established antibiotics. Deeper understanding of the varied mechanisms of action of these diverse peptides and the production of cost-effective, stable, and highly selective CAPs will aid in bringing these molecules closer to the clinic.
Aberg K. M. Radek K. A. Choi E. H. Kim D. K. Demerjian M. Hupe M. Kerbleski J. Gallo R. L. Ganz T. Mauro T. et al. 2007 Psychological stress downregulates epidermal antimicrobial peptide expression and increases severity of cutaneous infections in mice. 117 3339 3349
Andra J. Gutsmann T. Garidel P. Brandenburg K. 2006 Mechanisms of endotoxin neutralization by synthetic cationic compounds. 12 261 277
Andres M. T. Viejo-Diaz M. Fierro J. F. 2008 Human lactoferrin induces apoptosis-like cell death in Candida albicans: critical role of K+-channel-mediated K+ efflux. 52 4081 4088
Aung G. Niyonsaba F. Ushio H. Hoq M. I. Ikeda S. Ogawa H. Okumura K. 2011a A neuroendocrine antimicrobial peptide, catestatin, stimulates interleukin-8 production from human keratinocytes via activation of mitogen-activated protein kinases. 61 142 144
Aung G. Niyonsaba F. Ushio H. Kajiwara N. Saito H. Ikeda S. Ogawa H. Okumura K. 2011b Catestatin, a neuroendocrine antimicrobial peptide, induces human mast cell migration, degranulation and production of cytokines and chemokines. 132 527 539
Berge G. Eliassen L. T. Camilio K. A. Bartnes K. Sveinbjornsson B. Rekdal O. 2010 Therapeutic vaccination against a murine lymphoma by intratumoral injection of a cationic anticancer peptide 59 1285 1294
Bi L. Yang L. Narsimhan G. Bhunia A. K. Yao Y. 2011 Designing carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide 150 150 156
Bommarius B. Jenssen H. Elliott M. Kindrachuk J. Pasupuleti M. Gieren H. Jaeger K. E. Hancock R. E. Kalman D. 2010 Cost-effective expression and purification of antimicrobial and host defense peptides in Escherichia coli. 31 1957 1965
Braff M. H. Hawkins M. A. Di Nardo A. Lopez-Garcia B. Howell M. D. Wong C. Lin K. Streib J. E. Dorschner R. Leung D. Y. et al. 2005 Structure-function relationships among human cathelicidin peptides: dissociation of antimicrobial properties from host immunostimulatory activities. 174 4271 4278
Brocal I. Falco A. Mas V. Rocha A. Perez L. Coll J. M. Estepa A. 2006 Stable expression of bioactive recombinant pleurocidin in a fish cell line 72 1217 1228
Brogden K. A. 2005 Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? 3 238 250
Browne M. J. Feng C. Y. Booth V. Rise M. L. 2011 Characterization and expression studies of Gaduscidin-1 and Gaduscidin-2; paralogous antimicrobial peptide-like transcripts from Atlantic cod (Gadus morhua). 35 399 408
Bryksa B. C. Mac Donald. L. D. Patrzykat A. Douglas S. E. Mattatall N. R. 2006 A C-terminal glycine suppresses production of pleurocidin as a fusion peptide in Escherichia coli. 45 88 98
Burrowes O. J. Diamond G. Lee T. C. 2005 Recombinant expression of pleurocidin cDNA using the Pichia pastoris expression system. 3 74 384
Burrowes O. J. Hadjicharalambous C. Diamond G. Lee T. C. 2004 Evaluation of antimicrobial spectrum and cytotoxic activity of pleurocidin for food applications. 63 66 71
Cardini S. Dalli J. Fineschi S. Perretti M. Lungarella G. Lucattelli M. 2012 Genetic ablation of the Fpr1 gene confers protection from smoking-induced lung emphysema in mice. PMID 22461430
Castle M. Nazarian A. Yi S. S. Tempst P. 1999 Lethal effects of apidaecin on Escherichia coli involve sequential molecular interactions with diverse targets. 274 32555 32564
Cattaneo F. Iaccio A. Guerra G. Montagnani S. Ammendola R. 2011 NADPH-oxidase-dependent reactive oxygen species mediate EGFR transactivation by FPRL1 in WKYMVm-stimulated human lung cancer cells. 51 1126 1136
Ceron J. M. Contreras-Moreno J. Puertollano E. de Cienfuegos G. A. Puertollano M. A. de Pablo M. A. 2010 The antimicrobial peptide cecropin A induces caspase-independent cell death in human promyelocytic leukemia cells. 31 1494 1503
Chang T. W. Lin Y. M. Wang C. F. Liao Y. D. 2012 Outer membrane lipoprotein Lpp is Gram-negative bacterial cell surface receptor for cationic antimicrobial peptides. 287 418 428
Chen Z. Wang D. Cong Y. Wang J. Zhu J. Yang J. Hu Z. Hu X. Tan Y. Hu F. et al. 2011 Recombinant antimicrobial peptide hPAB-beta expressed in Pichia pastoris, a potential agent active against methicillin-resistant Staphylococcus aureus. 89 281 291
Cherkasov A. Hilpert K. Jenssen H. Fjell C. D. Waldbrook M. Mullaly S. C. Volkmer R. Hancock R. E. 2009 Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibiotic-resistant superbugs. 4 65 74
Chiou P. Khoo J. Bols N. C. Douglas S. Chen T. T. 2006 Effects of linear cationic alpha-helical antimicrobial peptides on immune-relevant genes in trout macrophages. 30 797 806
Cho J. Lee D. G. 2011a Oxidative stress by antimicrobial peptide pleurocidin triggers apoptosis in Candida albicans. 93 1873 1879
Cho J. Lee D. G. 2011b The antimicrobial peptide arenicin-1 promotes generation of reactive oxygen species and induction of apoptosis.
Chou H. T. Kuo T. Y. Chiang J. C. Pei M. J. Yang W. T. Yu H. C. Lin S. B. Chen W. J. 2008 Design and synthesis of cationic antimicrobial peptides with improved activity and selectivity against Vibrio spp. 32 130 138
Cirioni O. Silvestri C. Ghiselli R. Giacometti A. Orlando F. Mocchegiani F. Chiodi L. Vittoria A. D. Saba V. Scalise G. 2006 Experimental study on the efficacy of combination of alpha-helical antimicrobial peptides and vancomycin against Staphylococcus aureus with intermediate resistance to glycopeptides. 27 2600 2606
Cole A. M. Darouiche R. O. Legarda D. Connell N. Diamond G. 2000 Characterization of a fish antimicrobial peptide: gene expression, subcellular localization, and spectrum of activity. 44 2039 2045
Cole A. M. Weis P. Diamond G. 1997 Isolation and characterization of pleurocidin, an antimicrobial peptide in the skin secretions of winter flounder. 272 12008 12013
De Lucca A. J. Walsh T. J. 1999 Antifungal peptides: Novel therapeutic compounds against emerging pathogens 43 1 11
Dean R. E. O’Brien L. M. Thwaite J. E. Fox M. A. Atkins H. Ulaeto D. O. 2010 A carpet-based mechanism for direct antimicrobial peptide activity against vaccinia virus membranes. 31 1966 1972
den Hertog. A. L. van Marle J. van Veen H. A. Van’t Hof. W. Bolscher J. G. Veerman E. C. Nieuw Amerongen. A. V. 2005 Candidacidal effects of two antimicrobial peptides: histatin 5 causes small membrane defects, but LL-37 causes massive disruption of the cell membrane. 388 689 695
Douglas S. E. Gallant J. W. Gong Z. Hew C. 2001 Cloning and developmental expression of a family of pleurocidin-like antimicrobial peptides from winter flounder, Pleuronectes americanus (Walbaum). 25 137 147
Douglas S. E. Patrzykat A. Pytyck J. Gallant J. W. 2003 Identification, structure and differential expression of novel pleurocidins clustered on the genome of the winter flounder, Pseudopleuronectes americanus (Walbaum). 270 3720 3730
Dunham R. A. Warr G. W. Nichols A. Duncan P. L. Argue B. Middleton D. Kucuktas H. 2002 Enhanced bacterial disease resistance of transgenic channel catfish Ictalurus punctatus possessing cecropin genes. 4 338 344
Eckert R. 2011 Road to clinical efficacy: challenges and novel strategies for antimicrobial peptide development. 6 635 651
Eckert R. He J. Yarbrough D. K. Qi F. Anderson M. H. Shi W. 2006 Targeted killing of Streptococcus mutans by a pheromone-guided "smart" antimicrobial peptide. 50 3651 3657
Falla T. J. Zhang L. 2010 Efficacy of hexapeptide-7 on menopausal skin. 9 49 54
Faraj J. A. Dorati R. Schoubben A. Worthen D. Selmin F. Capan Y. Leung K. De Luca P. P. 2007 Development of a peptide-containing chewing gum as a sustained release antiplaque antimicrobial delivery system. 26
Fehlbaum P. Bulet P. Chernysh S. Briand J. P. Roussel J. P. Letellier L. Hetru C. Hoffmann J. A. 1996 Structure-activity analysis of thanatin, a 21-residue inducible insect defense peptide with sequence homology to frog skin antimicrobial peptides. 93 1221 1225
Feng Z. Jiang B. Chandra J. Ghannoum M. Nelson S. Weinberg A. 2005 Human beta-defensins: differential activity against candidal species and regulation by Candida albicans. 84 445 450
Fernandes J. M. Ruangsri J. Kiron V. 2010 Atlantic cod piscidin and its diversification through positive selection. 5, e9501.
Fischer P. M. 2003 The design, synthesis and application of stereochemical and directional peptide isomers: a critical review. 4 339 356
Fjell C. D. Jenssen H. Cheung W. A. Hancock R. E. Cherkasov A. 2011 Optimization of antibacterial peptides by genetic algorithms and cheminformatics 77 48 56
Fjell C. D. Jenssen H. Hilpert K. Cheung W. A. Pante N. Hancock R. E. Cherkasov A. 2009 Identification of novel antibacterial peptides by chemoinformatics and machine learning. 52 2006 2015
Gao G. Lange D. Hilpert K. Kindrachuk J. Zou Y. Cheng J. T. Kazemzadeh-Narbat M. Yu K. Wang R. Straus S. K. et al. 2011 The biocompatibility and biofilm resistance of implant coatings based on hydrophilic polymer brushes conjugated with antimicrobial peptides. 32 3899 3909
Garlapati S. Eng N. F. Kiros T. G. Kindrachuk J. Mutwiri G. K. Hancock R. E. Halperin S. A. Potter A. A. Babiuk L. A. Gerdts V. 2011 Immunization with PCEP microparticles containing pertussis toxoid, CpG ODN and a synthetic innate defense regulator peptide induces protective immunity against pertussis. 29 6540 6548
Ghiselli R. Giacometti A. Cirioni O. Mocchegiani F. Orlando F. D’Amato G. Sisti V. Scalise G. Saba V. 2004 Cecropin B enhances betalactams activities in experimental rat models of gram-negative septic shock. 239 251 256
Goldman M. J. Anderson G. M. Stolzenberg E. D. Kari U. P. Zasloff M. Wilson J. M. 1997 Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. 88 553 560
Guaní-Guerra E. Santos-Mendoza T. Lugo-Reyes S. O. Terán L. M. 2010 Antimicrobial peptides: general overview and clinical implications in human health and disease. 135 1 11
Hadley E. B. Hancock R. E. 2010 Strategies for the discovery and advancement of novel cationic antimicrobial peptides. 10 1872 1881
Haines L. R. Hancock R. E. W. Pearson T. W. 2003 Cationic antimicrobial peptide killing of African trypanosomes and Sodalis glossinidius, a bacterial symbiont of the insect vector of sleeping sickness. 3 175 186
Haines L. R. Thomas J. M. Jackson A. M. Eyford B. A. Razavi M. Watson C. N. Gowen B. Hancock R. E. Pearson T. W. 2009 Killing of trypanosomatid parasites by a modified bovine host defense peptide, BMAP-18 3 e373
Hancock R. E. Rozek A. 2002 Role of membranes in the activities of antimicrobial cationic peptides. 206 143 149
Harrington J. M. 2011 Antimicrobial peptide killing of African trypanosomes 33 461 469
Helmerhorst E. J. Troxler R. F. Oppenheim F. G. 2001 The human salivary peptide histatin 5 exerts its antifungal activity through the formation of reactive oxygen species 98 14637 14642
Hilchie A. L. Doucette C. D. Pinto D. M. Patrzykat A. Douglas S. Hoskin D. W. 2011 Pleurocidin-family cationic antimicrobial peptides are cytolytic for breast carcinoma cells and prevent growth of tumor xenografts. 13 R102
Hilpert K. Winkler D. F. Hancock R. E. 2007 Peptide arrays on cellulose support: SPOT synthesis, a time and cost efficient method for synthesis of large numbers of peptides in a parallel and addressable fashion. 2 1333 1349
Hirsch T. Spielmann M. Zuhaili B. Fossum M. Metzig M. Koehler T. Steinau H. U. Yao F. Onderdonk A. B. Steinstraesser L. et al. 2009 Human beta-defensin-3 promotes wound healing in infected diabetic wounds 11 220 228
Hoskin D. W. Ramamoorthy A. 2008 Studies on anticancer activities of antimicrobial peptides. 1778 357 375
Hua J. Yamarthy R. Felsenstein S. Scott R. W. Markowitz K. Diamond G. 2010 Activity of antimicrobial peptide mimetics in the oral cavity: I. Activity against biofilms of Candida albicans. 25 418 425
Huang H. N. Pan C. Y. Rajanbabu V. Chan Y. L. Wu C. J. Chen J. Y. 2011 Modulation of immune responses by the antimicrobial peptide, epinecidin (Epi)-1, and establishment of an Epi-1-based inactivated vaccine. 32 3627 3636
Huang L. C. Jean D. Mc Dermott A. M. 2005 Effect of preservative-free artificial tears on the antimicrobial activity of human beta-defensin-2 and cathelicidin LL-37 in vitro. 31 34 38
Hwang B. Hwang J. S. Lee J. Kim J. K. Kim S. R. Kim Y. Lee D. G. 2011a Induction of yeast apoptosis by an antimicrobial peptide, Papiliocin 408 89 93
Hwang B. Hwang J. S. Lee J. Lee D. G. 2011b The antimicrobial peptide, psacotheasin induces reactive oxygen species and triggers apoptosis in Candida albicans. 405 267 271
Imamura T. Yasuda M. Kusano H. Nakashita H. Ohno Y. Kamakura T. Taguchi S. Shimada H. 2010 Acquired resistance to the rice blast in transgenic rice accumulating the antimicrobial peptide thanatin 19 415 424
Imura Y. Choda N. Matsuzaki K. 2008 Magainin 2 in action: distinct modes of membrane permeabilization in living bacterial and mammalian cells 95 5757 5765
Ingham A. B. Moore R. J. 2007 Recombinant production of antimicrobial peptides in heterologous microbial systems. 47 1 9
Iwamuro S. Kobayashi T. 2010 An efficient protocol for DNA amplification of multiple amphibian skin antimicrobial peptide cDNAs. 615 159 176
Jenssen H. Hancock R. E. 2009 Antimicrobial properties of lactoferrin. 91 19 29
Jenssen H. Hancock R. E. 2010 Therapeutic potential of HDPs as immunomodulatory agents. 618 329 347
Jiang Z. Kullberg B. J. van der Lee H. Vasil A. I. Hale J. D. Mant C. T. Hancock R. E. Vasil M. L. Netea M. G. Hodges R. S. 2008 Effects of hydrophobicity on the antifungal activity of alpha-helical antimicrobial peptides. 72 483 495
Jin F. Xu X. Zhang W. Gu D. 2006 Expression and characterization of a housefly cecropin gene in the methylotrophic yeast, Pichia pastoris. 49 39 46
Jin X. Mei H. Li X. Ma Y. Zeng A. H. Wang Y. Lu X. Chu F. Wu Q. Zhu J. 2010 Apoptosis-inducing activity of the antimicrobial peptide cecropin of Musca domestica in human hepatocellular carcinoma cell line BEL-7402 and the possible mechanism. 42 259 265
Jung H. J. Park Y. Sung W. S. Suh B. K. Lee J. Hahm K. S. Lee D. G. 2007 Fungicidal effect of pleurocidin by membrane-active mechanism and design of enantiomeric analogue for proteolytic resistance. 1768 1400 1405
Kazemzadeh-Narbat M. Kindrachuk J. Duan K. Jenssen H. Hancock R. E. Wang R. 2010 Antimicrobial peptides on calcium phosphate-coated titanium for the prevention of implant-associated infections. 31 9519 9526
Kindrachuk J. Jenssen H. Elliott M. Townsend R. Nijnik A. Lee S. F. Gerdts V. Babiuk L. A. Halperin S. A. Hancock R. E. 2009 A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity. 27 4662 4671
Kindrachuk J. Napper S. 2010 Structure-activity relationships of multifunctional host defence peptides. 10 596 614
Knappe D. Henklein P. Hoffmann R. Hilpert K. 2010 Easy strategy to protect antimicrobial peptides from fast degradation in serum. 54 4003 4005
Koczulla R. von Degenfeld. G. Kupatt C. Krotz F. Zahler S. Gloe T. Issbrucker K. Unterberger P. Zaiou M. Lebherz C. et al. 2003 An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. 111 1665 1672
Lai Y. Gallo R. L. 2009 AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. 30 131 141
Lan Y. Ye Y. Kozlowska J. Lam J. K. Drake A. F. Mason A. J. 2010 Structural contributions to the intracellular targeting strategies of antimicrobial peptides. 1798 1934 1943
Lange C. F. Hancock R. E. Samuel J. Finlay W. H. 2001 In vitro aerosol delivery and regional airway surface liquid concentration of a liposomal cationic peptide. 90 1647 1657
Lee J. Lee D. G. 2008 Structure-antimicrobial activity relationship between pleurocidin and its enantiomer. 40 370 376
Lee J. Lee D. G. 2010 Influence of the hydrophobic amino acids in the N- and C-terminal regions of pleurocidin on antifungal activity. 20 1192 1195
Leontiadou H. Mark A. E. Marrink S. J. 2006 Antimicrobial peptides in action. 128 12156 12161
Li J. F. Zhang J. Song R. Zhang J. X. Shen Y. Zhang S. Q. 2009 Production of a cytotoxic cationic antibacterial peptide in Escherichia coli using SUMO fusion partner. 84 383 388
Li L. He J. Eckert R. Yarbrough D. Lux R. Anderson M. Shi W. 2010 Design and characterization of an acid-activated antimicrobial peptide. 75 127 132
Li M. Lai Y. Villaruz A. E. Cha D. J. Sturdevant D. E. Otto M. 2007 Gram-positive three-component antimicrobial peptide-sensing system. 104 9469 9474
Li M. Yu D. H. Cai H. 2008 The synthetic antimicrobial peptide KLKL5KLK enhances the protection and efficacy of the combined DNA vaccine against Mycobacterium tuberculosis. 27 405 413
Lienkamp K. Madkour A. E. Musante A. Nelson C. F. Nusslein K. Tew G. N. 2008 Antimicrobial polymers prepared by ROMP with unprecedented selectivity: a molecular construction kit approach. 130 9836 9843
Lim S. S. Song Y. M. Jang M. H. Kim Y. Hahm K. S. Shin S. Y. 2004a Effects of two glycine residues in positions 13 and 17 of pleurocidin on structure and bacterial cell selectivity. 11 35 40
Lipsky B. A. Holroyd K. J. Zasloff M. 2008 Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. 47 1537 1545
Liu S. Yang H. Wan L. Cai H. W. Li S. F. Li Y. P. Cheng J. Q. Lu X. F. 2011 Enhancement of cytotoxicity of antimicrobial peptide magainin II in tumor cells by bombesin-targeted delivery. 32 79 88
Lynn M. A. Kindrachuk J. Marr A. K. Jenssen H. Pante N. Elliott M. R. Napper S. Hancock R. E. Mc Master W. R. 2011 Effect of BMAP-28 antimicrobial peptides on Leishmania major promastigote and amastigote growth: role of leishmanolysin in parasite survival. 5 e1141
Mader J. S. Ewen C. Hancock R. E. Bleackley R. C. 2011 The human cathelicidin, LL-37, induces granzyme-mediated apoptosis in regulatory T cells. 34 229 235
Mai J. Tian X. L. Gallant J. W. Merkley N. Biswas Z. Syvitski R. Douglas S. E. Ling J. Li Y. H. 2011 A novel target-specific, salt-resistant antimicrobial peptide against the cariogenic pathogen Streptococcus mutans.
Makovitzki A. Fink A. Shai Y. 2009 Suppression of human solid tumor growth in mice by intratumor and systemic inoculation of histidine-rich and pH-dependent host defense-like lytic peptides. 69 3458 3463
Marcos J. F. Gandia M. 2009 Antimicrobial peptides: to membranes and beyond. 4 659 671
Marsh E. N. Buer B. C. Ramamoorthy A. 2009 Fluorine--a new element in the design of membrane-active peptides. 5 1143 1147
Mason A. J. Chotimah I. N. Bertani P. Bechinger B. 2006 A spectroscopic study of the membrane interaction of the antimicrobial peptide pleurocidin. 23 185 194
Mason A. J. Marquette A. Bechinger B. 2007 Zwitterionic phospholipids and sterols modulate antimicrobial peptide-induced membrane destabilization. 93 4289 4299
Mc Bride S. M. Sonenshein A. L. 2011 Identification of a genetic locus responsible for antimicrobial peptide resistance in Clostridium difficile. 79 167 176
Mc Phee J. B. Hancock R. E. 2005 Function and therapeutic potential of host defence peptides. 11 677 687
Mc Phee J. B. Lewenza S. Hancock R. E. 2003 Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa. 50 205 217
Menard S. Forster V. Lotz M. Gutle D. Duerr C. U. Gallo R. L. Henriques-Normark B. Putsep K. Andersson M. Glocker E. O. et al. 2008 Developmental switch of intestinal antimicrobial peptide expression. 205 183 193
Mogi T. Kita K. 2009 Gramicidin S and polymyxins: the revival of cationic cyclic peptide antibiotics. 66 3821 3826
Mor A. 2009 Multifunctional host defense peptides: antiparasitic activities. 276 6474 6482
Morash M. G. Douglas S. E. Robotham A. Ridley C. M. Gallant J. W. Soanes K. H. 2011 The zebrafish embryo as a tool for screening and characterizing pleurocidin host-defense peptides as anti-cancer agents. 4 622 633
Morton C. O. Dos Santos. S. C. Coote P. 2007a An amphibian-derived, cationic, alpha-helical antimicrobial peptide kills yeast by caspase-independent but AIF-dependent programmed cell death. 65 494 507
Morton C. O. Hayes A. Wilson M. Rash B. M. Oliver S. G. Coote P. 2007b Global phenotype screening and transcript analysis outlines the inhibitory mode(s) of action of two amphibian-derived, alpha-helical, cationic peptides on Saccharomyces cerevisiae. 51 3948 3959
Murakami T. Nakajima T. Koyanagi Y. Tachibana K. Fujii N. Tamamura H. Yoshida N. Waki M. Matsumoto A. Yoshie O. et al. 1997 A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. 186 1389 1393
Murray H. M. Leggiadro C. T. Douglas S. E. 2007 Immunocytochemical localization of pleurocidin to the cytoplasmic granules of eosinophilic granular cells from the winter flounder gill. 70 336 345
Mutwiri G. Gerdts V. Lopez M. Babiuk L. A. 2007 Innate immunity and new adjuvants. 26 147 156
Nguyen L. T. Chau J. K. Perry N. A. de Boer L. Zaat S. A. Vogel H. J. 2010 Serum stabilities of short tryptophan- and arginine-rich antimicrobial peptide analogs. 5 e12684
Nguyen L. T. Haney E. F. Vogel H. J. 2011The expanding scope of antimicrobial peptide structures and their modes of action. Trends Biotechnol 29 464 472
Nicolas P. 2009 Multifunctional host defense peptides: intracellular-targeting antimicrobial peptides. 276 6483 6496
Nijnik A. Hancock R. E. 2009 Host defence peptides: antimicrobial and immunomodulatory activity and potential applications for tackling antibiotic-resistant infections. 2 e1 7
Nizet V. 2006 Antimicrobial peptide resistance mechanisms of human bacterial pathogens. 8 11 26
Noga E. J. Ullal A. J. Corrales J. Fernandes J. M. 2011 Application of antimicrobial polypeptide host defenses to aquaculture: Exploitation of downregulation and upregulation responses. 6 44 54
Oono T. Shirafuji Y. Huh W. K. Akiyama H. Iwatsuki K. 2002 Effects of human neutrophil peptide-1 on the expression of interstitial collagenase and type I collagen in human dermal fibroblasts. 294 185 189
Park C. B. Yi K. S. Matsuzaki K. Kim M. S. Kim S. C. 2000 Structure-activity analysis of buforin II, a histone H2A-derived antimicrobial peptide: the proline hinge is responsible for the cell-penetrating ability of buforin II. 97 8245 8250
Park Y. Park S. C. Kim J. Y. Park J. O. Seo C. H. Nah J. W. Hahm K. S. 2010 In vitro efficacy of a synthetic all-d antimicrobial peptide against clinically isolated drug-resistant strains. 35 208 209
Patrzykat A. Friedrich C. L. Zhang L. Mendoza V. Hancock R. E. 2002 Sublethal concentrations of pleurocidin-derived antimicrobial peptides inhibit macromolecular synthesis in Escherichia coli. 46 605 614
Patrzykat A. Gallant J. W. Seo J. K. Pytyck J. Douglas S. E. 2003 Novel antimicrobial peptides derived from flatfish genes. 47 2464 2470
Patrzykat A. Zhang L. Mendoza V. Iwama G. K. Hancock R. E. 2001 Synergy of histone-derived peptides of coho salmon with lysozyme and flounder pleurocidin. 45 1337 1342
Peschel A. Sahl H. G. 2006 The co-evolution of host cationic antimicrobial peptides and microbial resistance. 4 529 536
Pieters R. J. Arnusch C. J. Breukink E. 2009 Membrane permeabilization by multivalent anti-microbial peptides. 16 736 742
Projan S. J. Bradford P. A. 2007 Late stage antibacterial drugs in the clinical pipeline. 10 441 446
Redfern R. L. Reins R. Y. Mc Dermott A. M. 2011 Toll-like receptor activation modulates antimicrobial peptide expression by ocular surface cells. 92 209 220
Riedl S. Rinner B. Asslaber M. Schaider H. Walzer S. Novak A. Lohner K. Zweytick D. 2011 In search of a novel target- phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy. 1808 2638 2645
Risso A. Zanetti M. Gennaro R. 1998 Cytotoxicity and apoptosis mediated by two peptides of innate immunity. 189 107 115
Rotem S. Mor A. 2009 Antimicrobial peptide mimics for improved therapeutic properties. 1788 1582 1592
Roy S. Das P. K. 2008Antibacterial hydrogels of amino acid-based cationic amphiphiles. Biotechnol Bioeng 100 756 764
Sa’adedin F. Bradshaw J. P. 2010 A differential scanning calorimetry study of the effects and interactions of antimicrobial peptide LS3 on phosphatidylethanolamine bilayers. 17 1345 1350
Saint N. Cadiou H. Bessin Y. Molle G. 2002 Antibacterial peptide pleurocidin forms ion channels in planar lipid bilayers. 1564 359 364
Schutte B. C. Mitros J. P. Bartlett J. A. Walters J. D. Jia H. P. Welsh M. J. Casavant T. L. Mc Cray P. B. Jr. 2002 Discovery of five conserved beta-defensin gene clusters using a computational search strategy. 99 2129 2133
Scott R. W. De Grado W. F. Tew G. N. 2008 De novo designed synthetic mimics of antimicrobial peptides. 19 620 627
Selsted M. E. Ouellette A. J. 2005 Mammalian defensins in the antimicrobial immune response. 6 551 557
Selvatici R. Falzarano S. Mollica A. Spisani S. 2006 Signal transduction pathways triggered by selective formylpeptide analogues in human neutrophils. 534 1 11
Shai Y. 2002 Mode of action of membrane active antimicrobial peptides. 66 236 248
Shai Y. Makovitzky A. Avrahami D. 2006 Host defense peptides and lipopeptides: modes of action and potential candidates for the treatment of bacterial and fungal infections. 7 479 486
Shen C. J. Kuo T. Y. Lin C. C. Chow L. P. Chen W. J. 2010 Proteomic identification of membrane proteins regulating antimicrobial peptide resistance in Vibrio parahaemolyticus. 108 1398 1407
Splith K. Neundorf I. 2011 Antimicrobial peptides with cell-penetrating peptide properties and vice versa. 40 387 397
Steinstraesser L. Burghard O. Nemzek J. Fan M. H. Merry A. Remick D. I. Su G. L. Steinau H. U. Wang S. C. 2003 Protegrin-1 increases bacterial clearance in sepsis but decreases survival. 31 221 226
Steinstraesser L. Koehler T. Jacobsen F. Daigeler A. Goertz O. Langer S. Kesting M. Steinau H. Eriksson E. Hirsch T. 2008 Host defense peptides in wound healing. 14 528 537
Sullivan R. Santarpia P. Lavender S. Gittins E. Liu Z. Anderson M. H. He J. Shi W. Eckert R. 2011 Clinical efficacy of a specifically targeted antimicrobial peptide mouth rinse: Targeted elimination of Streptococcus mutans and prevention of demineralization. 45 415 428
Sun B. J. Xie H. X. Song Y. Nie P. 2007 Gene structure of an antimicrobial peptide from mandarin fish, Siniperca chuatsi (Basilewsky), suggests that moronecidins and pleurocidins belong in one family: the piscidins. 30 335 343
Sung W. S. Lee D. G. 2008 Pleurocidin-derived antifungal peptides with selective membrane-disruption effect. 369 858 861
Syvitski R. T. Burton I. Mattatall N. R. Douglas S. E. Jakeman D. L. 2005 Structural characterization of the antimicrobial peptide pleurocidin from winter flounder. 44 7282 7293
Talukder P. Satho T. Irie K. Sharmin T. Hamady D. Nakashima Y. Kashige N. Miake F. 2011 Trace metal zinc stimulates secretion of antimicrobial peptide LL-37 from Caco-2 cells through ERK and 38MAP kinase. 141 144
Tani K. Shimizu T. Kida Y. Kuwano K. 2011 Mycoplasma pneumoniae infection induces a neutrophil-derived antimicrobial peptide, cathelin-related antimicrobial peptide. 55 582 588
Tao R. Tong Z. Lin Y. Xue Y. Wang W. Kuang R. Wang P. Tian Y. Ni L. 2011 Antimicrobial and antibiofilm activity of pleurocidin against cariogenic microorganisms. 32 1748 1754
Tavano R. Segat D. Gobbo M. Papini E. 2011 The honeybee antimicrobial peptide apidaecin differentially immunomodulates human macrophages, monocytes and dendritic cells.
Tay D. K. Rajagopalan G. Li X. Chen Y. Lua L. H. Leong S. S. 2011 A new bioproduction route for a novel antimicrobial peptide. 108 572 581
Tokumaru S. Sayama K. Shirakata Y. Komatsuzawa H. Ouhara K. Hanakawa Y. Yahata Y. Dai X. Tohyama M. Nagai H. et al. 2005 Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37. 175 4662 4668
Tomasinsig L. Scocchi M. Mettulio R. Zanetti M. 2004 Genome-wide transcriptional profiling of the Escherichia coli response to a proline-rich antimicrobial peptide. 48 3260 3267
Torrent M. Andreu D. Nogues V. M. Boix E. 2011 Connecting peptide physicochemical and antimicrobial properties by a rational prediction model. 6 e16968.
Tosteson M. T. Holmes S. J. Razin M. Tosteson D. C. 1985 Melittin lysis of red cells. 87 35 44
Turkoglu O. Kandiloglu G. Berdeli A. Emingil G. Atilla G. 2011 Antimicrobial peptide hCAP-18/LL-37 protein and mRNA expressions in different periodontal diseases. 17 60 67
van Beek W. P. Smets L. A. Emmelot P. 1973 Increased sialic acid density in surface glycoprotein of transformed and malignant cells--a general phenomenon? 33 2913 2922
van der Does A. M. Bogaards S. J. Ravensbergen B. Beekhuizen H. van Dissel J. T. Nibbering P. H. 2010 Antimicrobial peptide hLF1-11 directs granulocyte-macrophage colony-stimulating factor-driven monocyte differentiation toward macrophages with enhanced recognition and clearance of pathogens. 54 811 816
Venugopal D. 2010 Novel antimicrobial peptides that exhibit activity against select agents and other drug resistant bacteria. 18 5137 5147
Vylkova S. Nayyar N. Li W. Edgerton M. 2007 Human beta-defensins kill Candida albicans in an energy-dependent and salt-sensitive manner without causing membrane disruption. 51 154 161
Wallace D. F. Jones M. D. Pedersen P. Rivas L. Sly L. I. Subramaniam V. N. 2006 Purification and partial characterisation of recombinant human hepcidin. 88 31 37
Walsh E. G. Maher S. Devocelle M. O’Brien P. J. Baird A. W. Brayden D. J. 2011 High content analysis to determine cytotoxicity of the antimicrobial peptide, melittin and selected structural analogs. 32 1764 1773
Wang C. Li H. B. Li S. Tian L. L. Shang D. J. 2011 Antitumor effects and cell selectivity of temporin-1CEa, an antimicrobial peptide from the skin secretions of the Chinese brown frog (Rana chensinensis).
Wang G. Watson K. M. Peterkofsky A. Buckheit R. W. Jr 2010 Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database. 54 1343 1346
Wehkamp J. Harder J. Weichenthal M. Mueller O. Herrlinger K. R. Fellermann K. Schroeder J. M. Stange E. F. 2003 Inducible and constitutive beta-defensins are differentially expressed in Crohn’s disease and ulcerative colitis. 9 215 223
White J. H. 2010 Vitamin D as an inducer of cathelicidin antimicrobial peptide expression: past, present and future. 121 234 238
Wiesner J. Vilcinskas A. 2010 Antimicrobial peptides: the ancient arm of the human immune system. 1 440 464
Williams K. J. Bax R. P. 2009 Challenges in developing new antibacterial drugs. 10 157 163
Won A. Khan M. Gustin S. Akpawu A. Seebun D. Avis T. J. Leung B. O. Hitchcock A. P. Ianoul A. 2011a Investigating the effects of L- to D-amino acid substitution and deamidation on the activity and membrane interactions of antimicrobial peptide anoplin. 1808 1592 1600
Won H. S. Kang S. J. Choi W. S. Lee B. J. 2011b Activity optimization of an undecapeptide analogue derived from a frog-skin antimicrobial peptide. 31 49 54
Wu G. Li X. Deng X. Fan X. Wang S. Shen Z. Xi T. 2011 Protective effects of antimicrobial peptide S-thanatin against endotoxic shock in mice introduced by LPS. 32 353 357
Yala J. F. Thebault P. Hequet A. Humblot V. Pradier C. M. Berjeaud J. M. 2011 Elaboration of antibiofilm materials by chemical grafting of an antimicrobial peptide. 89 623 634
Yang D. Chen Q. Schmidt A. P. Anderson G. M. Wang J. M. Wooters J. Oppenheim J. J. Chertov O. 2000 LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. 192 1069 1074
Yang J. Y. Shin S. Y. Lim S. S. Hahm K. S. Kim Y. 2006 Structure and bacterial cell selectivity of a fish-derived antimicrobial peptide, pleurocidin. 16 880 888
Yang K. Gitter B. Ruger R. Wieland G. D. Chen M. Liu X. Albrecht V. Fahr A. 2011 Antimicrobial peptide-modified liposomes for bacteria targeted delivery of temoporfin in photodynamic antimicrobial chemotherapy. 10 1593 1560
Yarus S. Rosen J. M. Cole A. M. Diamond G. 1996 Production of active bovine tracheal antimicrobial peptide in milk of transgenic mice. 93 14118 14121
Yeung A. T. Gellatly S. L. Hancock R. E. 2011 Multifunctional cationic host defence peptides and their clinical applications. 68 2161 2176
Yevtushenko D. P. Romero R. Forward B. S. Hancock R. E. Kay W. W. Misra S. 2005 Pathogen-induced expression of a cecropin A-melittin antimicrobial peptide gene confers antifungal resistance in transgenic tobacco. 56 1685 1695
Yoon W. H. Park H. D. Lim K. Hwang B. D. 1996 Effect of O-glycosylated mucin on invasion and metastasis of HM7 human colon cancer cells. 222 694 699
Yoshida K. Mukai Y. Niidome T. Takashi C. Tokunaga Y. Hatakeyama Y. Aoyagi H. 2001 Interaction of pleurocidin and its analogs with phospholipid membrane and their antibacterial activity. 57 119 126
Zasloff M. 2002 Antimicrobial peptides of multicellular organisms. 415 389 395
Zasloff M. 2006 Inducing endogenous antimicrobial peptides to battle infections. 103 8913 8914
Zhang J. Yang Y. Teng D. Tian Z. Wang S. Wang J. 2011 Expression of plectasin in Pichia pastoris and its characterization as a new antimicrobial peptide against Staphyloccocus and Streptococcus. 78 189 196
Zhang L. Falla T. J. 2010 Potential therapeutic application of host defense peptides. 618 303 327